How frequent is altered gene expression among susceptibility genes to human complex disorders?

Genetics in Medicine

Volumn 7, Issue 2, 2005, Pages 83-96

  Jais, Philippe H ^a  

^a Chiasma Laboratories   (France)

Author keywords

Association; Expression; Microarrays; QTL; RNA

Indexed keywords

CLOZAPINE; TACRINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANOREXIA; ASTHMA; BIPOLAR DISORDER; BLADDER CANCER; BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG RESPONSE; EMPHYSEMA; ENDOCRINE DISEASE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HEAD AND NECK CANCER; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUNG CANCER; MALE INFERTILITY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OBESITY; OSTEOPOROSIS; PARKINSON DISEASE; PREECLAMPSIA; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

GENE EXPRESSION REGULATION; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; QUANTITATIVE TRAIT LOCI; RNA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 13844320621     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000153665.55420.C3     Document Type: Review

References (157)

1. Segal JA, Barnett JL, Crawford DL. Functional analyses of natural variation in Sp1 binding sites of a TATA-less promoter. J Mol Evol 1999;49:736-749.
2. Crawford DL, Segal JA, Barnett JL. Evolutionary analysis of TATA-less proximal promoter function. Mol Biol Evol 1999;16:194-207.
3. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA 2003;100:189-192.
4. Stephens JC, Schneider JA, Tanguay DA et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293:489-493.
5. Schadt EE, Monks SA, Drake TA et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 2003;422:297-302.
6. Korstanje R, Paigen B. From QTL to gene: The harvest begins. Nat Genet 2002;31:235-236.
7. Karp CL, Grupe A, Schadt E et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1:221-226.
8. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002;4:45-61.
9. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182.
10. Blacker D, Wilcox MA, Laird NM et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-360.
11. Inoue H, Ferrer J, Welling CM et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996;45:825-831.
12. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
13. Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992;184:9-15.
14. Bonithon-Kopp C, Ducimetiere P, Touboul PJ et al. Plasma angiotensin-converting enzyme activity and carotid wall thickening. Circulation 1994;89:952-954.
15. Casari G, Barlassina C, Cusi D et al. Association of the alpha-adducin locus with essential hypertension. Hypertension 1995;25:320-326.
16. Large V, Hellstrom L, Revnisdottir S et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997;100:3005-3013.
17. Walston J, Silver K, Bogardus C et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995;333:343-347.
18. Bonnardeaux A, Davies E, Jeunemaitre X et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-69.
19. Hegele RA, Huang LS, Herbert PN, et al. Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. N Engl J Med 1986;315:1509-1515.
20. Poduslo SE, Neal M, Herring K, Shelly J. The apolipoprotein CI A allele as a risk factor for Alzheimer's disease. Neurochem Res 1998;23:361-367.
21. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
22. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 1984;25:310-313.
23. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: A case-control study. Stroke 1993;24:661-664.
24. Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260-12264.
25. Schachter F, Faure-Delanef L, Guenot F et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.
26. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777-3782.
27. Stanford JL, Just JJ, Gibbs M et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-1198.
28. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-1936.
29. Smith MW, Dean M, Carrington M et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-965.
30. Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 1996;14:203-205.
31. Gutierrez B, Bertranpetit J, Guillamat R et al. Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Am J Psychiatry 1997;154:113-115.
32. Li T, Sham PC, Vallada H et al. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 1996;6:131-133.
33. Donner H, Rau H, Walfish PG et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;82:143-146.
34. Pullmann R, Jr., Lukac J, Skerenova M et al. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1999;17:725-729.
35. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998;97:135-137.
36. Tamaki S, Iwai N, Tsujita Y, Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 1999;33:266-270.
37. Ambrosone CB, Freudenheim JL, Graham S et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995;55:3483-34835.
38. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
39. Uematsu F, Kikuchi H, Motomiya M et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991;82:254-256.
40. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997;6:577-582.
41. Malhotra AK, Goldman D, Buchanan RW et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998;3:72-75.
42. Kennedy JL, Billett EA, Macciardi FM et al. Association study of dopamine D3 receptor gene and schizophrenia. Am J Med Genet 1995;60:558-562.
43. LaHoste GJ, Swanson JM, Wigal SB et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996;1:121-124.
44. Kurabayashi T, Tomita M, Matsushita H et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol 1999;180:1115-1120.
45. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
46. De Stefano V, Chiusolo P, Paciaroni K et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-3565.
47. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
48. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-905.
49. Moor E, Silveira A, van't Hooft F et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995;15:655-664.
50. Salmon JE, Millard S, Schachter LA et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-1354.
51. Hager J, Hansen L, Vaisse C et al. A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nat Genet 1995;9:299-304.
52. Hattersley AT, Turner RC, Permutt MA et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307-1310.
53. Siffert W, Rosskopf D, Siffert G et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998;18:45-48.
54. Sperr WR, Huber K, Roden M, et al. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 1998;90:117-123.
55. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993;85:1159-1164.
56. Anttila S, Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Nurminen T, Vainio H. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis 1994;15:1133-1135.
57. Groop LC, Kankuri M, Schalin-Jantti C, et al. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 1993;328:10-14.
58. Hinney A, Ziegler A, Nothen MM, Remschmidt H, Hebebrand J. 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity. Lancet 1997;350:1324-1325.
59. Arranz M, Collier D, Sodhi M et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346:281-282.
60. Inayama Y, Yoneda H, Sakai T et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67:103-105.
61. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF. Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1-receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. J Bone Miner Res 2000;15:402-414.
62. Zhu S, Chan-Yeung M, Becker AB et al. Polymorphisms of the 1L-4, TNF-alpha, and Fcepsilon RIbeta genes and the risk of allergic disorders in at-risk infants. Am J Respir Crit Care Med 2000;161:1655-1659.
63. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997;337:1720-1725.
64. Tsukamoto K, Yoshida H, Watanabe S et al. Association of radial bone mineral density with CA repeat polymorphism at the interleukin 6 locus in postmenopausal Japanese women. J Hum Genet 1999;44:148-151.
65. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33:176-183.
66. Hitman GA, Jowett NI, Williams LG, Humphries S, Winter RM, Galton DJ. Polymorphisms in the 5′-flanking region of the insulin gene and non-insulin-dependent diabetes. Clin Sci (Lond) 1984;66:383-388.
67. Imai Y, Fusco A, Suzuki Y et al. Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994;79:1655-1658.
68. Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996;335:1071-1072; author reply 1073-1074.
69. Bowen T, Guy CA, Craddock N et al. Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia. Mol Psychiatry 1998;3:266-269.
70. Li WD, Reed DR, Lee JH et al. Sequence variants in the 5′ flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet 1999;63:227-234.
71. Thorn JA, Chamberlain JC, Alcolado JC et al. Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis. Atherosclerosis 1990;85:55-60.
72. Vandevyver C, Raus P, Stinissen P, Philippaerts L, Cassiman JJ, Raus J. Polymorphism of the tumour necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis. Eur J Immunogenet 1994;21:377-382.
73. Sullivan KE, Wooten C, Goldman D, Petri M. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:2046-2051.
74. Boylan KB, Takahashi N, Paty DW et al. DNA length polymorphism 5′ to the myelin basic protein gene is associated with multiple sclerosis. Ann Neurol 1990;27:291-297.
75. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
76. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997;77:818-821.
77. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996;2:41-45.
78. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
79. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
80. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991;352:340-342.
81. Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet 1996;347:509-512.
82. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87:2520-2524.
83. Kalsheker NA, Hodgson IJ, Watkins GL, White JP, Morrison HM, Stockley RA. Deoxyribonucleic acid (DNA) polymorphism of the alpha 1-antitrypsin gene in chronic lung disease. BMJ (Clin Res Ed) 1987;294:1511-1514.
84. Morgan K, Morgan L, Carpenter K, et al. Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Hum Genet 1997;99:27-31.
85. Ishigami T, Umemura S, Iwamoto T et al. Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. Circulation 1995;91:951-954.
86. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180.
87. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-1855.
88. Li SR, Baroni MG, Oelbaum RS, Stock J, Galton DJ. Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988;2:368-370.
89. Lesch KP, Gross J, Franzek E, Wolozin BL, Riederer P, Murphy DL. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol Psychiatry 1995;37:215-223.
90. Moffatt MF, Cookson WO. Tumour necrosis factor haplotypes and asthma. Hum Mol Genet 1997;6:551-554.
91. Herrmann SM, Ricard S, Nicaud V et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998;28:59-66.
92. Hohler T, Kruger A, Schneider PM et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997;109:562-565.
93. Ilonen J, Merivuori H, Reijonen H et al. Tumour necrosis factor-beta gene RFLP alleles in Finnish IDDM haplotypes. The Childhood Diabetes in Finland (DiMe) Study Group. Scand J Immunol 1992;36:779-783.
94. Heijmans BT, Westendorp RG, Droog S, Kluft C, Knook DL, Slagboom PE. Association of the tumour necrosis factor alpha-308G/A polymorphism with the risk of diabetes in an elderly population-based cohort. Genes Immun 2002;3:225-228.
95. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-234.
96. Esterbauer H, Oberkofler H, Liu YM et al. Uncoupling protein-1 mRNA expression in obese human subjects: the role of sequence variations at the uncoupling protein-1 gene locus. J Lipid Res 1998;39:834-844.
97. Cassell PG, Neverova M, Janmohamed S, et al. An uncoupling protein 2 gene variant is associated with a raised body mass index but not Type II diabetes. Diabetologia 1999;42:688-692.
98. Cassell PG, Saker PJ, Huxtable SJ et al. Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in women of European and Asian origin. Diabetologia 2000;43:1558-1564.
99. Morrison NA, Qi JC, Tokita A et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-287.
100. Okuizumi K, Onodera O, Namba Y et al. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 1995;11:207-209.
101. Neri Serneri GG, Boddi M, Poggesi L et al. Activation of cardiac renin-angiotensin system in unstable angina. J Am Coll Cardiol 2001;38:49-55.
102. Petit-Turcotte C, Stohl SM, Beffert U,et al. Apolipoprotein C-I expression in the brain in Alzheimer's disease. Neurobiol Dis 2001;8:953-963.
103. Isoe K, Urakami K, Sato K, Takahashi K. Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. Acta Neurol Scand 1996;93:133-137.
104. Yamagata K, Urakami K, Ikeda K et al. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:57-62.
105. Zarow C, Victoroff J. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol 1998;149:79-86.
106. Hernandez I, Sokolov BP. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics. Mol Psychiatry 1997;2:57-64.
107. Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F. The abundance of mRNA for dopamine D2 receptor isoforms in brain tissue from controls and schizophrenics. Brain Res Mol Brain Res 1994;25:173-175.
108. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P. Schizophrenia: elevated mRNA for dopamine D2 (Longer) receptors in frontal cortex. Brain Res Mol Brain Res 2001;87:160-165.
109. Ilani T, Ben-Shachar D, Strous RD et al. A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A 2001;98:625-628.
110. Kwak YT, Koo MS, Choi CH, Sunwoo I. Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med Genet 2001;2:3.
111. Andreelli F, Laville M, Vega N, Riou JP, Vidal H. Regulation of gene expression during severe caloric restriction: lack of induction of p85 alpha phosphatidylinositol 3-kinase mRNA in skeletal muscle of patients with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 2000;43:356-363.
112. Ducluzeau PH, Perretti N, Laville M et al. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 2001;50:1134-1142.
113. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE. Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. Biochemical and molecular mechanisms. J Clin Invest 1996;98:1231-126.
114. Huang X, Vaag A, Hansson M, Weng J, Laurila E, Groop L. Impaired insulin-stimulated expression of the glycogen synthase gene in skeletal muscle of type 2 diabetic patients is acquired rather than inherited. J Clin Endocrinol Metab 2000;85:1584-1590.
115. Lofman M, Yki-Jarvinen H, Parkkonen M et al. Increased concentrations of glycogen synthase protein in skeletal muscle of patients with NIDDM. Am J Physiol 1995;269:E27-E32.
116. Vestergaard H, Bjorbaek C, Andersen PH, Bak JF, Pedersen O. Impaired expression of glycogen synthase mRNA in skeletal muscle of NIDDM patients. Diabetes 1991;40:1740-1745.
117. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2342-50.
118. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996;15:442-455.
119. Hernandez I, Sokolov BP. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J Neurosci Res 2000;59:218-225.
120. Glare EM, Divjak M, Rolland JM, Walters EH. Asthmatic airway biopsy specimens are more likely to express the IL-4 alternative splice variant IL-4delta2. J Allergy Clin Immunol 1999;104:978-982.
121. Humbert M, Durham SR, Ying S et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996;154:1497-1504.
122. Kotsimbos TC, Ernst P, Hamid QA. Interleukin-13 and interkukin-4 are coexpressed in atopic asthma. Proc Assoc Am Physicians 1996;108:368-373.
123. Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998;101:386-390.
124. Olivenstein R, Taha R, Minshall EM, Hamid QA. IL-4 and IL-5 mRNA expression in induced sputum of asthmatic subjects: comparison with bronchial wash. J Allergy Clin Immunol 1999;103:238-245.
125. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
126. Kotsimbos TC, Ghaffar O, Minshall EM et al. Expression of the IL-4 receptor alpha-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. J Allergy Clin Immunol 1998;102:859-866.
127. Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995;1:953-956.
128. Krempler F, Breban D, Oberkofler H et al. Leptin, peroxisome proliferator-activated receptor-gamma, and CCAAT/enhancer binding protein-alpha mRNA expression in adipose tissue of humans and their relation to cardiovascular risk factors. Arteriosder Thromb Vasc Biol 2000;20:443-449.
129. Montague CT, Prins JB, Sanders L, Digby JE, O'Rahilly S. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997;46:342-7.
130. Considine RV, Considine EL, Williams CJ et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995;95:2986-2988.
131. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
132. Lonnqvist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995;1:950-953.
133. Vidal H, Auboeuf D, De Vos P et al. The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest 1996;98:251-255.
134. Xu M, Zhong G, Fu Z et al. Molecular cloning, sequencing and expression of obese gene in the Chinese. Chin Med J (Engl) 2000;113:350-353.
135. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319-27.
136. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM. Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus. J Clin Invest 1998;101:543-548.
137. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 1997;46:1230-1234.
138. Sewter C, Blows F, Considine R, Vidal-Puig A, O'Rahilly S. Differential effects of adiposity on peroxisomal proliferator-activated receptor gamma1 and gamma2 messenger ribonucleic acid expression in human adipocytes. J Clin Endocrinol Metab 2002;87:4203-4207.
139. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416-2422.
140. Johnston JA, Froelich S, Lannfelt L, Cowburn RF. Quantification of presenilin-1 mRNA in Alzheimer's disease brains. FEBS Lett 1996;394:279-284.
141. Ikeda K, Urakami K, Isoe K, Ohno K, Nakashima K. The expression of presenilin-1 mRNA in skin fibroblasts from Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:145-148.
142. Ikeda K, Urakami K, Arai H et al. The expression of presenilin 1 mRNA in skin fibroblasts and brains from sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:245-250.
143. Davis D, Liyou N, Lockwood D, Johnson A. Angiotensinogen genotype, plasma protein and mRNA concentration in isolated systolic hypertension. Clin Genet 2002;61:363-368.
144. Sun Y, Zhang L, Johnston NL, Torrey EF, Yolken RH. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br J Psychiatry Suppl 2001;41:s137-s141.
145. Hube F, Birgel M, Lee YM, Hauner H. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1999;29:672-678.
146. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
147. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-2119.
148. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-E751.
149. Koistinen HA, Bastard JP, Dusserre E, et al. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur J Clin Invest 2000;30:302-310.
150. Oberkofler H, Dallinger G, Liu YM, Hell E, Krempler F, Patsch W. Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. J Lipid Res 1997;38:2125-2133.
151. Oberkofler H, Liu YM, Esterbauer H, Hell E, Krempler F, Patsch W. Uncoupling protein-2 gene: reduced mRNA expression in intraperitoneal adipose tissue of obese humans. Diabetologia 1998;41:940-946.
152. Millet L, Vidal H, Andreelli F et al. Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean humans. J Clin Invest 1997;100:2665-2670.
153. Nordfors L, Hoffstedt J, Nyberg B et al. Reduced gene expression of UCP2 but not UCP3 in skeletal muscle of human obese subjects. Diabetologia 1998;41:935-939.
154. Sbraccia P, D'Adamo M, Leonetti F, et al. Relationship between plasma free fatty acids and uncoupling protein-3 gene expression in skeletal muscle of obese subjects: in vitro evidence of a causal link. Clin Endocrinol (Oxf) 2002;57:199-207.
155. Vidal-Puig A, Rosenbaum M, Considine RC, Leibel RL, Dohm GL, Lowell BB. Effects of obesity and stable weight reduction on UCP2 and UCP3 gene expression in humans. Obes Res 1999;7:133-140.
156. Esterbauer H, Oberkofler H, Dallinger G et al. Uncoupling protein-3 gene expression: reduced skeletal muscle mRNA in obese humans during pronounced weight loss. Diabetologia 1999;42:302-309.
157. Millet L, Vidal H, Larrouy D, Andreelli F, Laville M, Langin D. mRNA expression of the long and short forms of uncoupling protein-3 in obese and lean humans. Diabetologia 1998;41:829-832.